Article Data

  • Views 501
  • Dowloads 122

Original Research

Open Access

The trend of chemotherapy-induced peripheral neurotoxicity in ovarian cancer survivors and its impacts on daily life during and one year after treatment

  • Y. Jing1
  • H.Y. Lv1
  • S.W. Feng1,*,

1Gynecology-Oncology Department, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, China

DOI: 10.12892/ejgo3267.2016 Vol.37,Issue 5,October 2016 pp.696-699

Published: 10 October 2016

*Corresponding Author(s): S.W. Feng E-mail: fengsw@zju.edu.cn

Abstract

Purpose: To explore the trend of progression and regression of peripheral neuropathy (PN) induced by combination of carboplatin and paclitaxel, and the impacts on daily activities. Materials and Methods: PN was evaluated by nurse-based interview and patient-reported measures in their diary. The severity of PN scaled by National Cancer Institute Common Toxicity Criteria (NCI-CTC) before each cycle of chemotherapy and at three, six, and 12 months after drug withdrawal and coded as Grade I ~ V. Results: The authors enrolled 106 eligible patients with ovarian cancer who underwent six cycles of combined chemotherapy of carboplatin plus paclitaxel. No patients showed Grade IV and V of PN and it was gradually aggravated following the dose accumulation. About 29.3% of the patients presented no PN, 64.2% Grade I, and 6.6% Grade II after the third course of chemotherapy, but increased to 36.8% of Grade I, 25.5% of Grade II, and 34.9% of Grade III after the sixth course of chemotherapy. At one-year follow-up, the rate of PN still existed with the rate of 88.5%, 57.3%, and 38.7% at three, six, and 12 months after drug withdrawal. Thirty-one patients encountered accidents, such as sharp injury (14.2%), fall (9.4%), burn (3.8%), and cold injury (1.9%). Conclusions: A significant proportion of patients with epithelial ovarian cancer treated with carboplatin plus paclitaxel suffer long term neuropathy and it affects patient's daily activities. Specialized care is necessary to provide not only during treatment, but also months to years after drugs withdrawal

Keywords

Peripheral neuropathy (PN); Chemotherapy; Ovarian cancer; Impact; Follow-up.

Cite and Share

Y. Jing,H.Y. Lv,S.W. Feng. The trend of chemotherapy-induced peripheral neurotoxicity in ovarian cancer survivors and its impacts on daily life during and one year after treatment. European Journal of Gynaecological Oncology. 2016. 37(5);696-699.

References

[1] Tofthagen C.: “Patient perceptions associated with chemotherapy induced peripheral neuropathy”. Clin. J. Oncol. Nurs., 2010, 14, E22.

[2] Argyriou A.A., Polychronopoulos P., Koutras A., Xiros N., Petsas T., Argyriou K., et al.: “Clinical and electro- physiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel- based chemotherapy”. Eur. J. Cancer Care (Engl.), 2007, 16, 23.

[3] Cancer Therapy Evaluation Program: “Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. March 31, 2003”. Publish date: August 9, 2006. Availbale at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

[4] Pignata S., De Placido S., Biamonte R., Scambia G., Di Vagno G., Colucci G., et al.: “Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxal: the Multicenter Italian trial in Ovarian cancer(MITO-4) retrospective study”. BMC Cancer, 2005, 6, 1.

[5] Argyriou A.A., Polychronopoulos P., Iconomou G., Koutras A., Kalofonos H.P., Chroni E.: “Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies”. J. Neurol., 2005, 252 1459.

[6] Ezendam N.P., Pijlman B., Bhugwandass C., Pruijt J.F., Mols F., Vos M.C., et al.: “Chemotherapy- induced peripheral neuropathy and itsimpact on health- related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry”. Gynecol. Oncol., 2014, 135, 510.

[7] Hershman D.L., Lacchetti C., Dworkin R.H., Lavoie E.M., Bleeker J., Cavaletti G., et al.: “Prevention and management of chemotherapyinduced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline”. J. Clin. Oncol., 2014, 32, 1941.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top